Average Weight Loss on Wegovy 0.25mg: What the Evidence Shows

Why 0.25mg is not where weight loss is measured

The STEP 1 trial, which formed the cornerstone of Wegovy's UK licence, enrolled nearly 1,961 adults with obesity or overweight and at least one weight-related condition. Participants followed a structured escalation: 0.25mg for four weeks, then 0.5mg, then 1.0mg, then 1.7mg, before reaching the 2.4mg maintenance dose at around week 16. Weight loss was tracked across the full 68 weeks. The headline figure (roughly 15% average body-weight reduction) belongs to the maintenance phase, not to the starting weeks.

At 0.25mg specifically, most people notice little change on the scales. That is not a sign the medicine is failing. Semaglutide works by activating GLP-1 receptors involved in appetite signalling and gastric emptying, but those effects build gradually as the dose rises. The 0.25mg period is essentially a calibration phase. Starting low reduces the nausea, vomiting and digestive discomfort that are common at higher doses, making the full course of treatment more tolerable and more likely to succeed.

If you are wondering whether something has gone wrong because the first four weeks brought little movement on the scales, the short answer is: nothing has gone wrong. The NHS semaglutide medicines page confirms that the starting dose is not intended to be therapeutic, it is a stepping stone.

How weight loss typically builds as the dose increases

The dose escalation schedule for Wegovy runs in roughly four-week steps, and noticeable appetite reduction tends to arrive somewhere between 0.5mg and 1.0mg for most people. By 1.0mg, many patients report their hunger patterns shifting, smaller portions feeling satisfying, the urge to snack easing. For a closer look at what the evidence shows at that point, the 1mg Wegovy weight loss page covers that stage in detail.

By the time someone reaches 1.7mg and then 2.4mg, the appetite-suppressing effect is at its most pronounced. If you are curious about what is the average dose of Wegovy for weight loss, it is worth understanding that the STEP 1 data showed a meaningful proportion of participants at maintenance dose lost more than 15% of their body weight, with some losing considerably more. Results vary between individuals depending on starting weight, dietary habits, activity levels and how well the dose is tolerated. Clinical guidance from NICE's appraisal of semaglutide (TA875) notes that patients who have not lost at least 5% of body weight after six months at the maintenance dose should have their treatment reviewed.

The point is that the trajectory matters more than any single weigh-in during the 0.25mg weeks. Jumping to conclusions about Wegovy's effectiveness during the starting period is like judging a long-distance run by the first hundred metres.

What to expect practically during the 0.25mg period

The first few weeks on Wegovy tend to be about adjustment rather than results. Some people experience mild nausea, loose stools or a slightly reduced appetite even at 0.25mg, side effects that are usually brief and settle as the body adapts. Others notice very little at all. Both experiences are normal. The medicine is taken as a once-weekly injection, and many people find it easier to build a routine around a fixed day, some patients pick Sunday evening so the first day or two of any adjustment falls at home rather than at work.

It is worth being honest with your prescriber if side effects are bothering you, because the titration pace can sometimes be adjusted. Slowing progression through the dose schedule is preferable to stopping treatment altogether. A clear overview of how the full escalation works, including a breakdown of the average dose of Wegovy at each stage, is set out on the Wegovy doses page, including what each level involves. If you have questions about whether 0.25mg is the right starting point for your circumstances, the general FAQs cover common queries, or you can speak directly with a prescriber.

For patients thinking about the longer-term picture (including what happens if weight loss stalls or a dose reduction becomes necessary) the page on reducing your Wegovy dose explains the clinical thinking behind that decision.

Private access versus NHS routes, and the cost question

Wegovy is available on the NHS, but access follows the criteria set out in NICE TA875 and requires referral to a specialist weight management service; waiting times vary considerably. Private prescribing through a regulated online pharmacy is an alternative for people who do not meet those criteria or prefer not to wait. If cost is a factor in your thinking, the Wegovy cost context page sets out what private treatment typically involves and what to look for in a provider.

Any pharmacy you consider should be verifiable on the GPhC register. Wegovy is a prescription-only medicine, and legitimate suppliers require a proper clinical assessment before dispensing, not just an online questionnaire with no follow-up. If you are ready to find out whether Wegovy is suitable for you, our prescribers are available to review consultations the same day. Speak to our prescribers and get a clear answer on where you stand.